Purpose
The Federal Bureau of Prisons (BOP) Clinical Practice Guidelines for the Prevention and Treatment of Hepatitis A provide recommendations for the medical management of federal inmates with hepatitis A virus (HAV) infection, and for prevention for those who are at risk of infection.
Transmission
HAV is transmitted fecal-orally and is acquired either by person-to-person contact or by the ingestion of contaminated food or water. Individuals at increased risk of acquiring HAV infection include the following groups.
Risk Factors for Hepatitis A Infection
• persons consuming contaminated food or water • men who have sex with other men • persons who inject illegal drugs • persons with clotting disorders who require clotting-factor concentrates • individuals who are close personal contacts of infected persons
Those persons who are newly infected with HAV are most contagious during the two weeks prior to the onset of jaundice. The presence of diarrhea increases contagiousness. Transmission can readily occur through close personal contact such as sexual exposure or by sharing contaminated communal surfaces, such as toilets. HAV remains viable in the environment for weeks to months.
Hepatitis A Infectious Period
The infectious period for acute hepatitis A extends from two weeks before hepatitis symptom onset until two weeks after symptom onset.
The prevalence of previously acquired HAV infection among inmate populations is estimated at 22-39% and is largely associated with either the inmate's community of origin or the inmate's high-risk behaviors. American Indians, Alaskan Natives, and many persons from Latin America, Africa, the Middle East, China, and Southeast Asia come from communities with endemic HAV infection, where infection by early adulthood is commonplace.
In the United States, the incidence of new HAV infections is at an historic low, but clusters of hepatitis A cases continue to occur via community-based outbreaks. The highest rates of new HAV infections occur in the Western United States, and in large urban areas among men who have sex with men. Institutional outbreaks of hepatitis A are primarily limited to settings with children and have generally not involved correctional facilities. 
Natural History
The incubation period is the period of time from infection with HAV until the onset of hepatitis symptoms.
Hepatitis A Incubation Period The average incubation period for hepatitis A is 28 days (ranging from 15-50 days).
Initial, prodromal symptoms include fatigue, malaise, nausea, vomiting, anorexia, fever, and right upper quadrant pain. After 3-7 days, patients develop dark urine, light-colored stools, jaundice, and pruritus. The prodromal symptoms usually subside with the onset of jaundice, which typically peaks within 2 weeks. In symptomatic patients, laboratory findings are notable for significant elevations of serum direct bilirubin, total bilirubin, and serum aminotransferases (usually >1000 IU/dL).
HAV infection usually leads to an acute, self-limited illness and only rarely to fulminant hepatic failure. HAV generally is not associated with relapsing or cholestatic clinical illness. The risk of fulminant hepatic failure is significantly increased for those with underlying liver disease, particularly for those with chronic hepatitis C infection. Of those with acute hepatitis A, approximately 85% have a full clinical and biochemical recovery within 3 months; nearly all have a complete recovery in 6 months. Natural lifelong immunity develops following resolution of acute hepatitis A.
Diagnosis
Individuals who present with symptoms of hepatitis should be tested for IgM anti-HAV, HBsAg, IgM anti-HBc, and anti-HCV. Two serologic tests for hepatitis A are commercially available. 
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Treatment
No effective antiviral therapies are available for acute hepatitis A. Therefore, treatment efforts are largely supportive. Fulminant, acute hepatitis A may be complicated by protracted nausea and vomiting, dehydration, high fever, impaired consciousness, and liver failure (the latter requiring intensive care hospitalization). Any inmate with acute HAV infection should be evaluated daily by a health care provider for signs and symptoms of liver failure, i.e., changes in mental status, vomiting, and dehydration.
Prevention
Hepatitis A vaccine should be considered for certain high-risk inmates at the first preventive health visit. Appendix 1 provides an overview of hepatitis A vaccination, including a list of inmate risk factors that should prompt offering hepatitis A vaccination to the inmate; it also provides guidance regarding dosing and administration. Hepatitis A vaccine is not routinely indicated for inmate workers who are plumbers or food service workers.
Infection Control Reporting
Each institution should have a surveillance system for notifiable infectious diseases in accordance with BOP policy. All cases of acute hepatitis A should be reported to state health authorities, as required by all the states and the Commonwealth of Puerto Rico. Acute cases of hepatitis A should also be reported to the Central Office Health Services Division (HSD) in accordance with BOP policy.
Containment
An inmate diagnosed with acute hepatitis A should be considered contagious and be isolated until the end of the infectious period-two weeks after the onset of their hepatitis symptoms. Inmates diagnosed with acute hepatitis A should be managed in accordance with the following guidelines.
Hepatitis A Infection Control Guidelines
• Isolate the inmate in a single cell with a separate sink and toilet (e.g., a single cell in segregation) until two weeks after the onset of symptoms and until clinically improving without diarrhea.
• Immediately remove the inmate from any assigned duties as a food handler.
• Counsel the inmate regarding the importance of strict hand washing and other practical infection control measures.
• Utilize standard precautions to prevent fecal-oral transmission to others entering the inmate's cell. This includes using gloves, gowns, and other personal protective equipment if contact with the inmate's body fluids is anticipated, e.g., changing soiled linens, cleaning toilets, etc.
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Contact Investigations
A BOP contact investigation, in consultation with local or state public health authorities, is required for any inmate with acute hepatitis A who was incarcerated during the infectious period. For acute hepatitis A, the index case should be assumed to have been communicable for the time period extending from two weeks before symptom onset until two weeks after symptom onset. The purpose of the contact investigation is to identify close contacts of the index case during the infectious period and, if indicated, to provide prophylaxis. Close contacts are defined as: cellmate(s), sexual contacts, persons routinely sharing toilet facilities, those sharing injection drugs, and those who have shared eating utensils, and (if the index case was a food handler) coworker food handlers.
Food handlers in the facility should be evaluated to determine if they could have been the source of the hepatitis A infection. Every food handler (employees and inmates) should be interviewed to determine if they are currently ill with hepatitis symptoms (fever, malaise, anorexia, nausea, abdominal discomfort, or jaundice), or if they have had hepatitis symptoms during the 15-50 days preceding the onset of symptoms in the index case. An IgM anti-HAV should be obtained from any food service worker reporting a history of hepatitis symptoms. The facility's local health department should be directly involved in any potential food-borne outbreak to help determine the need for broad-based immunoprophylaxis.
Detailed steps for conducting a hepatitis A contact investigation are delineated in Appendix 2a.
A sample contact line-list for hepatitis A is provided in Appendix 2b.
Post-Exposure Management
• Indications: The following susceptible contacts of an index case of hepatitis A are candidates for post-exposure prophylaxis. 
Candidates for Hepatitis A Post-Exposure Prophylaxis

Co-worker food handlers (if the index case is a food handler)
More broad-based immunoprophylaxis of inmates and correctional staff may be indicated if the index case was a food handler (in consultation with local and state public health authorities and the Central Office).
• Post-exposure prophylaxis guidelines: Until recently, an injection of immune globulin (IG) was the only recommended way to protect people after they had been exposed to the hepatitis A virus. The BOP guidelines have been revised to recommend hepatitis A vaccine as an alternative to prevent infection after HAV exposure, particularly for healthy persons who are age 40 or younger.
Persons who are eligible for post-exposure prophylaxis are those who have been exposed to HAV, and who have neither been vaccinated previously nor had a history of hepatitis A.
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The guidelines for use of vaccine versus IG vary both by age and by health status as outlined below. Administer either a dose of single-antigen hepatitis A vaccine or a dose of IG (0.02 mL/kg)
Post Exposure Prophylaxis Guidelines by Age and Health Status
Healthy inmates who are age 40 and under
Single-antigen hepatitis A vaccine is preferred over IG because of the advantages of the vaccine-long-term protection, ease of administration, increased availability, and equivalent efficacy to IG. For persons who receive the vaccine, the second vaccine dose should be administered to complete the series according to the licensed schedule (see Appendix 1).
Inmates older than age 40, or immunocompromised, or diagnosed with chronic liver disease IG is preferred over vaccine because in these groups there is both inadequate data on vaccine efficacy and greater potential for development of severe hepatitis. However, it is acceptable to use vaccine in the event that IG cannot be obtained.
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Definitions
Hepatitis A is an acute viral hepatitis caused by a highly infectious RNA virus, and transmitted primarily by the fecal-oral route and close personal contact. Acute hepatitis A has a mild to fulminant clinical presentation that resolves without progression to chronic infection or chronic hepatitis.
HAV is the hepatitis A virus.
IgG anti-HAV are antibodies to HAV that confer immunity.
IgM anti-HAV is the antibody subclass to HAV that develops with acute symptomatic and subclinical infection. False positive IgM anti-HAV serologies can occur.
Incubation period is the period of time between infection and the onset of symptoms. For acute hepatitis A, the average incubation period is 28 days (range: 15-50 days).
Index case is the first case of a contagious disease in a group or population that serves to call attention to the presence of the disease.
Infectious Period is the period of time when infection can be transmitted. For acute hepatitis A, individuals should be assumed to have been communicable starting two weeks before symptom onset, and continuing to be communicable until two weeks after symptom onset.
Standard precautions are protective measures to be used for all patient/inmate contacts and situations in which infections can be transmitted by contaminated blood and body fluids. Precautions include:
(1) the wearing of gloves and other personal protective equipment that provide an impervious barrier when soiling is likely; (2) procedures for protective handling (i.e., using puncture-resistant devices and leak-proof protection) of contaminated materials and equipment; and (3) routine cleaning of all contaminated surfaces and equipment.
Total anti-HAV are total antibodies to HAV, including both the IgG and the IgM antibody subclasses. Determine the number of inmates that were housed together, characterize the housing arrangements and the toilet facilities for the likelihood of transmission, and determine the availability of data regarding the inmates who were in contact with the hepatitis A case.
Evaluate contacts for their need for post-exposure prophylaxis.
Identified close contacts, which have neither been vaccinated previously nor have a history of hepatitis A, are eligible for post-exposure prophylaxis. They should be administered either a dose of single-antigen hepatitis A vaccine or a dose of immune globulin (IG) (0.02 mL/kg). Post-exposure prophylaxis should be administered as soon as possible and within two weeks after the exposure.
The selection of vaccine versus IG should be based on age and health status:
• For healthy inmates up to age 40 years: Single-antigen hepatitis A vaccine is preferred over IG. (See Appendix 1 for vaccine overview.) • For inmates older than age 40, or immunocompromised, or with chronic liver disease: IG is preferred. However, if IG is unavailable, vaccine can be used.
Determine if case was preventable.
Was patient a contact of a person with acute hepatitis A? G Yes G No
